Peptides as a drug modality offer several advantages over both traditional small molecules and biologics including improved tissue penetration, simpler more modular design characteristics, accessing previously intractable targets and reduced immunogenic risks. The advancement of peptides as therapeutics has been aided by the development of peptide drug conjugates, and this event brings together world class and cutting edge scientists in the fields of peptide and peptide macrocyclic drug and drug conjugate research. The event will give insights into the challenges posed and also the potential for these drugs to make a real world impact, and to interact with active researchers.
This event will be of interest to academic and industrial scientists, interested in learning the latest innovations in the field of peptide and peptide macrocyclic drug and drug conjugate developments.
Thursday 25 April
- Registration and refreshments
- Introduction and welcome
Dr Mark Frigerio, Bicycle Therapeutics
- Combining physicochemical measures with natural intelligence to achieve better efficacy with large molecules
Dr Rob Young, Blue Burgundy Ltd
- Cyclic peptide discovery in a more native context
Dr Louise Walport, The Francis Crick Insititute
- Lunch, exhibition and posters
- Bugs, plants and peptides: unleashing the power of chemical ecology for sustainable crop protection
Dr Aurelien Bigot, Syngenta Crop Protection
- Peptide conjugates for oncology focussed on radionucleotides
Dr Gemma Mudd, Bicycle Therapeutics
- Refreshment break, exhibition and posters
- Platforms for the intracellular generation and high-throughput screening of cyclic peptide libraries
Professor Ali Tavassoli, Chief Scientific Officer and Co-Founder, Curve Therapeutics
- Design and optimization of highly potent, orally bioavailable, PCSK9 macrocycle inhibitors as LDL-cholesterol lowering therapeutics
Dr Elisabetta Bianchi, IRBM
- Peptides as antibody mimics
Sir Gregory Winter, Medical Research Council (MRC) Laboratory of Molecular Biology
- Networking reception
SCI’s Fine Chemicals Group are committed to promoting diversity and equality in the chemical sciences. We aim to identify high quality speakers for all our conferences with full inclusivity where attendees from all backgrounds are welcome. We are open to offering flexible presentation options.
Sponsorship and exhibition information
For further information and prices, please email email@example.com.
Call for posters
Opportunities are available for a limited number of posters. Interested applicants should send an abstract of maximum one A4 page or 300 words, indicating title and authors to: firstname.lastname@example.org
by Thursday 29 February 2024
with the subject line “New modalities: Innovations in peptides as biotherapeutics – poster submission”. An abstract template can be downloaded here.
Venue and Contact
Before early bird - ends 14 March 2024
SCI Member - £75
Non-member - £130
SCI Student member - £40
After early bird
SCI Member - £125
Non-member - £180
SCI Student member - £70
Become an SCI Member and save on this and future events
See Membership Options
Sign up as an Event Member to join this event. SCI Full or Student Members receive discounts on event registrations
Booking terms and conditions
SCI Members attending this meeting are able to claim CPD points.
Beatriz Dominguez, SCI / Johnson Matthey
Mark Frigerio, SCI / Bicycle Therapeutics
Helen Horsley, SC I /UCB
Kenneth Ling, SCI / Syngenta
Sarah Major, SCI / Dark Blue Therapeutics